Fast Track designation and IND clearance are positive catalysts that reduce regulatory risk and enable US enrollment. Traders should monitor for the full week-100 results in H2 2026, which will be the next major binary event.
Price Chart
Executive Summary
AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active immunotherapy ACI-7104 for early Parkinson's disease. The ongoing Phase 2 VacSYn trial showed positive interim safety and immunogenicity data (100% responder rate), with full week-100 results expected in H2 2026. This regulatory milestone de-risks the program and enables US trial expansion, but the stock's poor historical reaction to catalysts warrants tempered expectations.
Key Facts
- FDA Fast Track designation granted for ACI-7104 in early-stage Parkinson's disease
- IND clearance allows expansion of Phase 2 VacSYn trial to US sites
- Interim Phase 2 data at 76 weeks showed safety, tolerability, and 100% immunogenicity responder rate
- Full week-100 results from Part 1 of VacSYn trial expected in H2 2026
- Company received a $4 million research grant from Vijay and Marie Goradia Charitable Foundation for trial extension
Financial Impact
No financial figures provided; regulatory milestone may increase probability of success and potential future partnership value, but no immediate revenue impact
Risk Factors
- Phase 2 trial results may not meet efficacy endpoints
- Competition from other alpha-synuclein targeting therapies
- Company may require additional financing to complete development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001651625-26-000016 |
| Document: aciu-20260811xex99d1.htm | 0001651625-26-000016 |
| Document: 0001651625-26-000016-index-headers.html | 0001651625-26-000016 |
| Document: 0001651625-26-000016-index.html | 0001651625-26-000016 |
| Document: 0001651625-26-000016.txt | 0001651625-26-000016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.25 (−8.16%) |
Oct 9, 2026 18d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.25 (−10.00%) |
Oct 2, 2026 25d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.25 (−17.43%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.25 (−20.49%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.25 (−23.21%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.25 (−14.77%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.25 (−14.77%) |
Aug 11, 2026 11w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.25 (−11.42%) |
Aug 11, 2026 11w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.25 (−11.42%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.25 (−1.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers